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Abstract 
Aims: Injection drug users (IDU’s) are at high risk for chronic hepatitis C virus infection 
(CHC). Opioid maintenance treatment (OMT) offers a unique opportunity to screen for CHC. 
This study proposed the hypothesis that a GP with special interest in addiction medicine can 
achieve CHC screening rates comparable to specialized centres and aimed to investigate 
determinants for a successful CHC case finding in a primary care setting. 
Design: Retrospective medical record analysis.  
Participants, setting: 387 patients on OMT (self-reported IDU prevalence of 61.2% ) 
between January 2002 and May 2008 in a general practice in Zurich, Switzerland.  
Measurements: Successful CHC assessment was defined as performance of HCV 
serology with consecutive PCR-based RNA and genotype recordings depending on serology. 
Socio-demographics, degree of employment, illicit drug use and psychiatric co-morbidity 
have been assessed. The association between screening success and patient characteristics was 
investigated by multiple logistic regression. 
Findings: Median (IQR) age and duration of OMT of the 387 (268 males) patients was 
38.5 (22.1-60.5) years and 34 (11.3-68) months, respectively. 14 patients (3.6%) denied HCV 
testing and informed consent about screening was missing in 13 patients (3.4%). In 327 of 
360 patients (90.8%) with informed consent a successful CHC assessment has been 
performed. Screening for HCV antibodies was positive in 136 cases (41.6 %) and in 86 of 
them (63.2%) a CHC  was present. The duration of OMT was an independent determinant of 
a successful CHC assessment.  
Conclusions: In addicted patients a high CHC assessment rate in a primary care setting 
in Switzerland is feasible and opioid substitution provides an optimal framework.  
 
Keywords: general practice, hepatitis C, methadone substitution, primary care, opioid 
dependence, screening 
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 1. Introduction 
Hepatitis C virus (HCV) infection and its progression to chronic hepatitis C (CHC) is a 
major cause of chronic liver disease and responsible for a high amount of morbidity and 
mortality in the world 1. Injection drug users (IDU’s) are at high risk for HCV infection and 
they will significantly contribute to the patient group with end-stage liver disease (ESLD) in 
the future 2.  
Opioid maintenance treatment (OMT) is established in the therapy of substance abuse 
and associated with a reduction in illicit drug use, HIV risk behaviour and drug-related 
criminal activities 3. In addition OMT has been shown to be an effective framework for 
adherence and virological success in HIV treatment 4 5 and preventing tuberculosis in patients 
with HIV 6. There is increasing evidence of a similar therapeutic response to CHC treatment 
in patients on OMT, including patients with active IDU, compared to patients without drug 
dependence 7-10. In light of the latest treatment evidence, effective CHC case finding becomes 
an important prerequisite to provide HCV care to this high risk population with the potential 
to prevent a significant number of patients from ESLD. 
In Switzerland a policy of low-threshold for OMT access has been promoted since the 
1990s in response to the HIV epidemic and the majority of patients are treated by general 
practitioners (GP) 11 12. However concerns have been raised about the quality of management 
as one study indicated that patients treated in specialized centres in Switzerland were more 
likely to receive screening for HCV compared to GP’s 13 which contrasts results from USA, 
Australia and the United Kingdom 14-16. We hypothesized that in Switzerland a GP with a 
high level of commitment but without a special intervention can achieve CHC assessment 
rates comparable to specialized centres in opioid addicts (with and without a history of  IDU) . 
In addition we aimed to assess patient characteristics including duration of OMT which were 
associated with successful CHC assessment in a primary care setting. 
2. Methods 
Retrospective analysis of patients who received opioid maintenance therapy (methadone, 
buprenorphine or morphine retard) between  January 1, 2002 through May 31, 2008. Prior to 
the OMT patients were asked for their informed consent in an anonymous data analysis thus 
approval by the local ethic committee was not necessary.  
Health care system and patient selection 
Addicted patients from a single-handed general practice located in Zurich, Switzerland 
providing standard medical services in addition to an office-based official OMT for opioid 
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addicted patients. During the study period more than 2500 patients without substance abuse 
have been treated and OMT has been offered to 492 patients.  
Opioid-maintenance treatment 
Methadone, buprenorphine and morphine were prescribed. The OMT regimen was based 
on a computer-assisted drug prescription and delivery system (CDDD) that provides a patient 
tailored dosage regime within a safety framework allowing the patients to choose dosage 
within an individualised maximal daily dose 17. According to the patients day structure 
dispensing and ingestion was observed on a daily or weekly basis (except on weekends).  
Primary outcome measurements  
A complete CHC assessment was the primary outcome of the study. The following 
criteria based on the patient record review defined a successful CHC assessment: 
1. A negative HCV antibody screening test 
2. A non-detectable HCV viral load based on a polymerase-chain reaction (PCR) 
method if HCV antibodies were positive 
3. Documentation of the HCV genotype in patients with diagnosed CHC (i.e. HCV 
antibody and RNA positive) 
Assessment of patient characteristics 
OMT-related data (i.e. duration, average dose) could be accessed and further processed 
from CDDD. Demographics, psychiatric co-morbidities (based on clinical grounds), self-
declared addiction-specific variables (i.e. ever and current IDU, concomitant other drug and 
alcohol abuse), and social- and occupational characteristics (i.e. housing situation, 
employement based on a written proof) were assessed by systematic review of patient records.  
Statistical analysis 
Testing for CHC is not the primary focus during initiation of OMT and adherence to 
OMT has been shown to stabilise after 3 months of treatment 18 therefore we restricted our 
analysis on patients who were at least 3 months on opioid substitution. 
Shapiro-Wilk test was applied to check for Gaussian distribution of the continuous 
variables and data are presented as medians and interquartile ranges (IQR) when non-
normally distribution was present. According to the definition of successful CHC assessment 
above patients were categorized into 2 groups (i.e. successful CHC assessment vs. failed CHC 
assessment). Non-parametric group comparisons were performed to evaluate differences 
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between patient characteristics. A multiple logistic model was used to assess the independent 
associations between CHC assessment success and patient characteristics (Stata Vers. 10.0).  
3. Results 
Baseline characteristics of the 387 patients (n=268 males) who were more than 3 months 
on OMT between January 1, 2002 and May 31, 2008 are shown in Table 1. Median (IQR) age 
and age at first opioid use was 38.5 (33.6-44.5) and 33.2 (28-39) years, respectively. A vast 
majority of the patients (87.9%) was on methadone maintenance treatment and 50 patients 
(12.9%) experienced more than 1 opioid for long-term substitution. The median (IQR) 
duration on OMT was 34 (11.3-68) months with a wide range between 3.1 to 310.9 months. 
During the study period median prescription for methadone, buprenorphine and morphine was 
70 (48-105), 6.4 (3.2-9.6), and 360.5 (215.7-512.4) milligram, respectively. Psychiatric co-
morbidity was high with about a third suffering from an unstable disorder and one third 
having a stable condition with or without treatment. IDU was reported of about two thirds of 
the patients but only a minority (9.8%) currently injected drugs. Additional drug abuse or 
excessive alcohol consumption was present in 77 patients (19.9%). Most of the patients had a 
permanent residence with part- or fulltime employment. 
 
CHC assessment rate and determinants of successful screening 
Of the 387 patients 14 patients (3.6%) denied a testing for CHC and missing information 
about informed screening consent was present in 13 patients (3.4%); therefore the following 
analysis was restricted to 360 patients. In 327 out of 360 patients (90.8%) on OMT of more 
than 3 months a successful CHC assessment could be performed. Reasons for unsuccessful 
CHC assessment (n=33) was a missing HCV antibody screening test in 6 patients, no 
additional RNA testing in 3 patients with antibody detection and lack of HCV genotyping in 
24 patients with CHC.  
Group comparisons between patients with successful CHC assessment and patients with 
failed assessments are presented in Table 2. Duration of OMT and employability were 
significantly higher in patients with successful CHC assessment whereas the prevalence of 
other drug and alcohol misuse, IDU, and unstable psychiatric co-morbidity were significantly 
higher in patients where CHC assessment failed. The methadone dose did not differ between 
groups. In a multiple logistic regression analysis including all potential determinants of 
successful CHC assessment (as presented in Table 2) as covariates only months of OMT 
remained significantly and positively associated with successful CHC assessment revealing an 
OR (95% CI) of 1.017 (1.002-1.032) (p=0.028).  The median dose of methadone during the 
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study period was significantly higher in patients with unstable psychiatric disorders (p for 
group comparison <0.001) and in patients misusing other drugs (p<0.05 for cocaine, 
benzodiazepines, IDU ever) or with alcohol excess (p=0.01) suggesting a complex 
interrelationship between methadone dose, patient characteristics and success of CHC 
assessment. 
 
HCV prevalence and HIV-co-infection 
Based on the 327 patients with a successful CHC assessment the screening for HCV 
antibodies was positive in 136 cases (41.6 %) and in 86 of them (63.2%) a CHC  (i.e. 
detection of HCV RNA) was present which represents a prevalence of CHC of 26.3%. HCV 
genotype 1and 3 were most common with 43 (50%) and 34 (39.5%) cases, respectively. HCV 
genotype 4 was responsible for the remaining 9 cases (9.5%). In 20 out of the 110 patients 
with HCV infection HIV co-infection was present (18.1%). 
4. Discussion 
This study examined patient characteristics in an unselected population at high risk for 
hepatitis C infection in a single-handed general practice in Switzerland. A complete CHC 
assessment including determination of HCV-RNA and HCV-genotype depending on the 
antibody screening test was feasible in the vast majority of patients on OMT. The duration of 
OMT was independently and positively associated with successful CHC assessment . The 
observed screening rate of 90.8% compares favourable to the HCV antibody screening rate of 
77.9% that was found in a survey of specialized centres offering OMT for opioid addicts in 
Switzerland 13 but contrasts the significantly lower HCV testing by GP’s offering OMT in the 
aforementioned study (reported test rate 66.2%). Follow-up patients in the specialized centres 
reported a higher rate of ongoing injection drug use (18.2% for heroin, 19.8% for cocaine) 
compared to our sample (current IDU 9.8%) supposing that our GP patients were more stable 
in comparison to patients attending a specialised clinic. However long-term OMT patients 
(minimum follow-up of 2 years) in a specialised outpatient clinic providing low-threshold 
substitution in Zurich, Switzerland, showed 3 different patterns of concomitant heroine, 
cocaine and alcohol abuse in an individual longitudinal analysis 19. This clinical relevant 
information cannot be supplied by cross-sectional data only. We can not provide solid 
information about our patients’ selection criteria for choosing the current OMT programme. 
Patients experienced institutional and GP settings. This fluctuation rate is well known and 
representative for the current study area where different intervention programmes exist.  
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Our results support the hypothesis that in Switzerland the described lower HCV testing 
by GP’s compared to specialized centres is probably a lack of awareness rather than a 
problem of the health care setting. GP’s concerns about adherence to CHC treatment and 
expected side effects might explain reluctance to address HCV screening. Inadequate self-
assessed knowledge by GP’s treating opioid addicts and the growing evidence of a safe and 
effective antiviral CHC treatment in IDU’s suggest a lack of education and does not question 
the role of the GP in HCV-related care in patients on OMT 20 21. The high rate of complete 
CHC assessment in our study can not be attributed to a specific intervention program focusing 
on HCV-related care in general practice but may be explained by the high level of 
commitment of the attending GP with a special interest in addiction medicine. Besides drug-
related medical and social problems the high prevalence of psychiatric comorbidities is 
typical for patients on OMT. Patients are often not willing to be referred to other institutions 
or specialists for further diagnostics and treatments. Providing chronic care (i.e. substitution, 
treatment of psychiatric comorbidities) in combination of acute somatic care  (i.e. 
gynecological- and infectious related care) in the same setting reduces adherence- and loss to 
follow-up problems. We believe that the “holistic” approach which is a main feature of a 
primary care setting is another reason for the achieved success.  
We found an independent and positive association between a successful CHC assessment 
and the duration of OMT. Thus, a patient spending 34 months (i.e. the median duration of 
OMT of the study population) on opioid substitution has a nearly 80% (i.e. OR 1.017 34) 
increased chance to be HCV tested compared to a patient just fulfilling the inclusion criteria 
of minimal 3 months on substitution. OMT has been shown to be associated with increased 
adherence and virological success in HIV treatment 4 5 and in the successful implementation 
of chemoprophylaxis for patients at high risk for active tuberculosis 6. Our results further 
strengthened OMT as a favourable therapeutic setting expanding its role for HCV-related 
care.  
The doses of substitute treatments were on the lower recommended range. The OMT 
regimen in our study was based on a computerised dispensing of opioid allowing the patients 
to choose dosage within an individualised safety maximal daily dose. Thus the observed 
dosages reflect patients preferences taking into account patients subjectively perceived 
benefits rather than prescribed dosages by the GP.  Lewis and colleagues 16 showed that 
general practice patients with similar drug using backgrounds were more likely to remain in 
an opioid substitution treatment after 20 months compared to patients treated in a drug clinic. 
In addition mean methadone dose in the GP patients was significantly lower at the end of 
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study compared to the drug clinic patients (i.e. 39 mls vs. 46 mls daily) indicating that the 
OMT benefit can not only be reduced to a pure dose effect but also pointed out the important 
role of the setting. 
The analysis of the current study was based on data of a single-handed general practice 
and therefore does not address effectiveness of CHC assessment in the primary care setting as 
opposed to a specialized clinic and generalization of the results might be questioned. 
Nevertheless several reasons indicate that the achieved results might be relevant to a broader 
primary care setting. 1) Our study population has similar characteristics with regard to age, 
HCV prevalence, illicit (non-IDU) drug use and psychiatric co-morbidities compared to GP 
patients  in other OMT programmes in Switzerland 12  23 and the UK 16. 2) We achieved a high 
eligibility rate of  76.6% (OMT duration of less than 3 months was the only exclusion criteria) 
which is an important characteristic in the evaluation of  the external validity. 3) Our results 
have been achieved in a “real world” setting (i.e. no specific intervention focusing on HCV-
related care was implemented). Although based on a single practice experience we believe 
that due to the high eligibility rate and the representative patient population our study 
provided evidence that OMT can result in a high rate of successful CHC assessment.in a 
Swiss GP setting. We are not aware of a study that assessed the specific role of an OMT 
programme in the context of HCV-related care. Our results are in line with the well-known 
beneficial role of OMT in HIV-related care in specialized centers thus we suggest that long-
term OMT in the context of CHC case finding might be desirable for specialized settings as 
well.   
We conclude that a high rate of  CHC assessment in unselected patients on OMT is 
feasible in a primary care setting in Switzerland. The independent association between OMT 
duration and successful CHC assessment highlights the important role of opioid substitution 
as a therapeutic framework to optimize CHC case finding in this high risk population.  
Declaration of interest 
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Table 1: Characteristics of patients >3 months on opioid maintenance treatment (OMT) 
Demographics % (n) or median (IQR) * 
Male 69.3 (268) 
Age (years) 38.5 (33.6-44.5) 
Opioid maintenance therapy (OMT):  
Age beginning OMT (years) 33.2 (28.0-39.0) 
Methadone as last OMT medication 87.9 (340) 
Buprenorphin as last OMT medication 9.3 (36) 
Morphin as last OMT medication 2.8 (11) 
Use of >1 different opioid in the past 12.9 (50) 
Duration of OMT (months) 34 (11.3-68.0) 
Average methadone dose during OMT (mg) 70 (48-105) 
Psychiatric comorbidity:  
No psychiatric disorder 29.5 (114) 
Stable disorder without treatment 15.8 (61) 
Stable disorder under treatment 19.9 (77) 
Unstable disorder 34.4 (133) 
Injection drug use (IDU):  
Ever 61.2 (237) 
Current 9.8 (38) 
Other drug and excessive alcohol use:  
Heroin 31.0 (120) 
Cocaine 23.3 (90) 
Benzodiazepines 15.3 (59) 
Alcohol 28.7 (111) 
Occupational and social variables:  
Employability (%)  80 (40-100) 
Single household  42.4 (164) 
Shared household  51.7 (200) 
Other  4.7 (18) 
* Maximum sample size 387, differences reflect missing information 
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Table 2: Determinants of successful HCV assessment in patients >3 months on OMT 
Determinants Success (n=327)*
% (n) or median 
(IQR)  
Failure (n=33)* 
% (n) or median 
(IQR]) 
P-value#
Demographics:    
Male 69.4 (227) 66.7 (22)  
Female 30.6 (100) 33.3 (11) 0.74 
Age (years) 38.5 (34.1-44.3) 39.2 (31.2-42.9) 0.58 
Age beginning OMT (years) 33.2 (28.1-39) 32.4 (26.8-36.8) 0.54 
Opiate maintenance therapy:    
Methadone 89.9 (294) 81.8 (27)  
Buprenorphin 7.3 (24) 15.2 (5)  
Morphin 2.8 (9) 3.0 (1) 0.21 
Single OMT therapy 87.2 (285) 87.9 (29)  
Use of >1 different opiate in the past 12.8 (42) 12.8 (4) 1.0 
Duration of OMT (months) 39 (14.4-74)† 19 (7-36) 0.003 
Average methadone dose during OMT (mg) 70.2 (47.9-106.1) 76.6 (48.4-95.3) 0.55 
Psychiatric comorbidity:    
None or stable disorder  67 (219) 59.4 (13)  
Unstable disorder 33 (108) 40.6 (19) 0.003 
Drug injected:    
Ever, yes 61 (199) 84.9 (28)  
Ever, no 39 (127) 15.1 (5) 0.007 
Current, yes 8 (26) 30.3 (10)  
Current, no 92 (301) 69.7 (23) <0.001 
Other drug and excessive alcohol use:    
Current heroin use 28.1 (92) 53.1 (17)  
No heroin use 71.9 (235) 46.9 (15) 0.003 
Current cocaine use 2.7 (71) 46.9 (15)  
No cocaine use 78.3 (256) 53.1 (17) 0.001 
Current benzodiazepine use 15.3 (50) 21.9 (7)  
No benzodiazepine use 84.7 (276) 78.1 (25) 0.335 
Excessive alcohol use 27.8 (91) 46.9 (15)  
No alcohol excess 72.2 (236) 53.1 (17) 0.024 
Occupational and social variables:    
Employability (%) 80 (40-100) 50 (30-80) 0.014 
Single household 43.2 (141) 41.9 (13)  
Shared household  52.5 (171) 48.4 (15)  
Other 4.3 (14) 9.7 (3) 0.34 
* Maximum sample size 360, patients refusing HCV screening (n=14) and with missing informed 
consent (n=13) were excluded; differences reflect missing information #group comparisons by 
Chi-square or Fisher exact as appropriate and Mann-Whitney test; † remained independently 
associated with succesful HCV screening after controlling for age, sex, psychiatric comorbidity, 
IDU, drug and alcohol use, employability and housing with an OR (95% CI) of 1.017 (1.002-
1.032) (p=0.028) 
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